Radiology and oncology · 2026
Conversion therapy for advanced hepatocellular carcinoma following complete response to transarterial radioembolization combined with atezolizumab and bevacizumab.
СтатьяКлинический случайНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Popovic Peter, Kalamutova Ana, Djokic Mihajlo, Cuderman Anka, Boltezar Gasper, Trotovsek Blaz
Аннотация
BACKGROUND: The current Barcelona Clinic Liver Cancer (BCLC) classification recommends systemic treatment with atezolizumab and bevacizumab as the first-line therapy for advanced hepatocellular carcinoma (HCC). Recent studies suggest that combining systemic immunotherapy with locoregional treatments, such as transarterial radioembolization (TARE), may enhance immune responses and improve overall treatment outcomes. This article presents a case series of three patients with advanced hepatocellular carcinoma who were treated with transarterial radioembolization followed by atezolizumab and bevacizumab achieving conversion to surgical resection.
PATIENTS AND METHODS: Between June 2020 and April 2024, three patients with advanced HCC were treated with TARE followed by atezolizumab and bevacizumab. The cohort included: Patient 1: A 59-year-old female, with noncirrhotic liver, with a 12 cm tumor and a 1.5 cm satellite lesion located in the liver, with hepatic vein and inferior vena cava (IVC) tumor thrombosis (Vv3 Japanese classification) and a small lung metastasis. Patient 2: A 63-year-old male with chronic hepatitis C (CHV), presenting with a 10 cm tumor and portal vein tumor thrombosis (Vp4 Japanese classification). Patient 3: A 50-year-old male, with non-cirrhotic liver, with a 17 cm tumor with portal vein and IVC tumor thrombosis (Vp3, Vv3 Japanese classification).
RESULTS: The combined treatment approach enabled surgical resection in all three patients, each achieving a complete pathological response. Interestingly, follow-up dosimetric analysis showed that all tumors had received a subtherapeutic absorbed radiation doses.
CONCLUSIONS: In selected patients, combining transarterial radioembolization with systemic immunotherapy may enable conversion to surgical resection in advanced hepatocellular carcinoma, even with subthreshold tumor radiation doses, highlighting a potential synergistic and abscopal effect between locoregional and systemic therapies.
PATIENTS AND METHODS: Between June 2020 and April 2024, three patients with advanced HCC were treated with TARE followed by atezolizumab and bevacizumab. The cohort included: Patient 1: A 59-year-old female, with noncirrhotic liver, with a 12 cm tumor and a 1.5 cm satellite lesion located in the liver, with hepatic vein and inferior vena cava (IVC) tumor thrombosis (Vv3 Japanese classification) and a small lung metastasis. Patient 2: A 63-year-old male with chronic hepatitis C (CHV), presenting with a 10 cm tumor and portal vein tumor thrombosis (Vp4 Japanese classification). Patient 3: A 50-year-old male, with non-cirrhotic liver, with a 17 cm tumor with portal vein and IVC tumor thrombosis (Vp3, Vv3 Japanese classification).
RESULTS: The combined treatment approach enabled surgical resection in all three patients, each achieving a complete pathological response. Interestingly, follow-up dosimetric analysis showed that all tumors had received a subtherapeutic absorbed radiation doses.
CONCLUSIONS: In selected patients, combining transarterial radioembolization with systemic immunotherapy may enable conversion to surgical resection in advanced hepatocellular carcinoma, even with subthreshold tumor radiation doses, highlighting a potential synergistic and abscopal effect between locoregional and systemic therapies.